arrow
D

David A. Braun

Yale School of Medicine
H指数:36
被引数:7,405

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

11 Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)

11 OMNIVORE试验的长期随访:适应性纳武利尤单抗和伊匹木单抗在晚期肾细胞癌中的疗效(NCT03652142)

2026-09-020
OAAI
70 Lymphocyte Hsp70 is a Novel Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma

70 淋巴细胞Hsp70是转移性肾细胞癌对免疫检查点抑制剂反应的新型预测生物标志物

2026-09-020
OAAI
16 ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy

16 ABBV-CLS-484:一种新型口服PTPN2/1抑制剂用于癌症免疫疗法

2026-09-020
OAAI
75 Transcriptional Correlates of ARNT Expression and its Impact on Survival Outcomes in Clear-Cell Renal Cell Carcinoma (ccRCC)

75 ARNT表达的相关转录特征及其对透明细胞肾细胞癌(ccRCC)生存结局的影响

2026-09-020
OAAI
51 Discovery of Exhausted CD8+ T-cell States Associated with Clinical Outcomes in Renal Cell Carcinoma

51 与肾细胞癌临床结局相关的耗竭CD8+ T细胞状态的发现

2026-09-020
OAAI
8 Single Cell Transcriptomic Investigation of Renal Cell Carcinoma (RCC) Reveals Tissue Resident Memory Exhausted CD8+ T Cell Signature Associated with Resistance to Immune Checkpoint Inhibition (ICI)

8 单细胞转录组学分析揭示肾细胞癌(RCC)中与免疫检查点抑制(ICI)耐药性相关的组织驻留记忆耗竭型CD8+ T细胞特征

2026-09-020
OAAI
Distinct endogenous retroviruses are expressed in mutational subtypes of clear cell renal cell carcinoma and are linked to improved clinical outcomes

不同内源性逆转录病毒在透明细胞肾细胞癌的突变亚型中表达,并与改善的临床结局相关

2026-08-010
OAAI
Tertiary lymphoid structures harbour stem-like tumour-specific T cells

三级淋巴结构中存在干细胞样肿瘤特异性T细胞

Nature
IF48.5
2026-07-220
PRE
Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells

单核多模态空间转录组学揭示表达新抗原的肿瘤细胞与其配体T细胞的共定位

2026-07-220
PRE
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results

HPK1抑制剂NDI-101150单药治疗及联合帕博利珠单抗治疗晚期实体瘤患者的Ⅰ/Ⅱ期试验结果

2026-05-060
OAAI
A live tumor fragment platform to assess immunotherapy response in core needle biopsies while addressing challenges of tumor heterogeneity

一种评估核心针活检中免疫治疗反应并解决肿瘤异质性挑战的活肿瘤片段平台

2026-01-030
OA
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma

MLH1错配修复缺陷预测透明细胞肾细胞癌对免疫检查点抑制的显著反应

2025-11-040
PRE